OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
February 05, 2020
Synthetic biology can help researchers circumvent the challenges of traditional methods of antibody generation.
The knockout CHO K1 cell line will be used to support biotherapeutic R&D across a range of therapeutic indications.
February 02, 2020
Bio/pharma researchers mobilize to diagnose and treat patients in pandemic threat.
Researching excipient grades and sources, as well as screening suppliers and materials, form the basis of programs to mitigate risk.
February 01, 2020
The need for manufacturing speed inspires contract manufacturers to explore advanced processing technologies.
January 31, 2020
The partners will collaborate on developing scale-up chip-based technology to enable commercial-scale production of a third-generation DNA synthesis platform.
The license gives Daiichi Sankyo access to ERS Genomics’ genome-editing technology for internal R&D initiatives.
Otsuka will use PhoreMost’s phenotypic screening platform to identify new targets for drug development, with a focus on gene therapy.
January 23, 2020
Fios Genomics, a spin-out bioinformatics company from Edinburgh University, has entered into a strategic partnership with Charles River Laboratories.
January 22, 2020
Mereo BioPharma Group and Oncologie have entered a global licensing agreement for the development and commercialization of navicixizumab.